Vaxart, Inc. (VXRT)
After hours:
| Previous close | 0.7662 |
| Open | 0.7700 |
| Bid | 0.7362 x 800 |
| Ask | 0.7503 x 200 |
| Day's range | 0.7201 - 0.7720 |
| 52-week range | 0.5300 - 1.5900 |
| Volume | |
| Avg. volume | 1,687,662 |
| Market cap | 130.577M |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5700 |
| Earnings date | 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 09 Nov 2012 |
| 1y target est | 5.00 |
GlobeNewswireVaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2024 after the market close on Monday, May 13, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate:
- GlobeNewswire
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through passive antibody transfer SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed the topline analysis for the Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate. The trial was focused on lactating mothers. Antibodies to norovirus rose on average 4.0 fold for
- GlobeNewswire
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024. The Company has appeared repeatedly at the annual event in Washington, D.C. Presentation Information: Title: Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccinationSpeaker: Dr. Sean
